Technology & Platform
At the heart of Mucommune are two core platforms. The first is the “muco-trapping” mAb platform that harnesses Fc-mucin interactions to immobilize viruses, bacteria and sperm in mucus, thereby effectively reinforcing the mucus barrier. The approach has been validated against a variety of pathogens across all major mucosal secretions, with in vivo proof-of-concept in both small and large animal models. The second is our expertise in developing intravaginal rings (IVRs) that can be tailored to provide month-long sustained release of a diverse array of therapeutics while preserving their stability. These platforms enable us to develop first-in-class interventions that can address a variety of unmet needs in female reproductive health with exceptional potency, safety and user-friendliness.